Nathan Weinstein

Nathan Weinstein

Managing Director & Head of Healthcare Equity Research
Mr.Weinstein is Head of Healthcare Equity Research at Aegis Capital Corp. Mr. Weinstein has over a decade of experience in equities. Mr. Weinstein was formerly Vice President, Institutional Equities and Head of Alpha Capture at CL King & Associates and an Institutional Equities Salesperson at Sidoti & Company. At those firms, Mr. Weinstein facilitated equity research distribution, proprietary long/short idea flow, and corporate access for mutual, pension, and hedge fund clients. Mr. Weinstein began his career as a research intern at NGN Capital, a life sciences venture capital fund. Mr. Weinstein graduated from Binghamton University with a BA in Economics and English, and from New York University’s Stern School of Business with an MBA (finance concentration). Additionally, Mr. Weinstein holds the CFA designation, and the Series 7, 63, 86, and 87 licenses.

Companies Covered (By Industry)


ATAI atai Life Sciences N.V.
CDTX Cidara Therapeutics, Inc.
CING Cingulate, Inc.
CMMB Chemomab Therapeutics Ltd.
CYBN Cybin, Inc.
ENTX Entera Bio Ltd.
ENVB Enveric Biosciences, Inc.
EVGN Evogene Ltd.
GLSI Greenwich LifeSciences, Inc.
HROW Harrow Health, Inc.
IMUX Immunic, Inc.
MDWD MediWound Ltd.
ORMP Oramed Pharmaceuticals, Inc.
KTRA Kintara Therapeutics, Inc.
SPRC SciSparc Ltd.
XOMA XOMA Corporation


VNRX VolitionRX Ltd.

Digital Therapeutics

DRIO DarioHealth Corp.

Medical Devices

AVGR Avinger, Inc.
IINN Inspira Technologies Oxy B.H.N. Ltd.